Learn

Despite the robustness of the literature on the topic, Australian clinicians and their patients still have a long way to go in optimising the management of dyslipidaemia. 50% of Australians have a total cholesterol above 5 mmol/l and 57.5% of Australians in the high cardiovascular risk category are not appropriately treated for their risk factors.

This educational video explores the state of dyslipidaemia management in Australia via a panel-based discussion and will cover the prevalence, causes and impacts of poor lipid control and explore the barriers to optimal lipid-lowering. The myriad treatment options will be discussed, suggesting a rational and structured approach to lipid-lowering, including the role of PCSK9 inhibitors and emerging medication options. Panellists discuss the conundrum of the lack of definitive Australian lipid-lowering guidelines, and how cardiologists and GPs can collaborate on assertive cholesterol-lowering to the benefit of their patients.

Sponsor: This activity is sponsored by Novartis. 

Learning Outcomes

1. Describe the current state of dyslipidaemia in Australia, including prevalence, causes and impacts on health outcomes
2. List the current treatment options for cholesterol lowering and a framework for rational and target informed prescribing
3. Outline the barriers to definitive lipid-lowering, ways of troubleshooting those, and methods for collaboration with general practitioners.

Details

Disclaimer: Please note, once you click 'Register now' you will be leaving the AMA’s CPD Home website and entering a third-party education provider’s website. If you choose to register for this learning, you will need to provide some of your personal information directly to the third-party education provider. If you have any queries about how third-party education providers use, disclose or store your personal information you should consult their privacy policy.

Upon completion, your CPD activity record may take up to 48 hours to be reflected on your CPD Home Dashboard.